Overview

OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors

Status:
Completed
Trial end date:
2009-12-21
Target enrollment:
Participant gender:
Summary
RATIONALE: OGX-011 may kill tumor cells by blocking some of the proteins that may cause tumor cells to grow. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving OGX-011 together with docetaxel may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of OGX-011 when given together with docetaxel in treating patients with metastatic or locally recurrent solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
NCIC Clinical Trials Group
Treatments:
Docetaxel